[go: up one dir, main page]

WO2015020191A1 - Agent calcique - Google Patents

Agent calcique Download PDF

Info

Publication number
WO2015020191A1
WO2015020191A1 PCT/JP2014/071005 JP2014071005W WO2015020191A1 WO 2015020191 A1 WO2015020191 A1 WO 2015020191A1 JP 2014071005 W JP2014071005 W JP 2014071005W WO 2015020191 A1 WO2015020191 A1 WO 2015020191A1
Authority
WO
WIPO (PCT)
Prior art keywords
calcium
acid
magnesium
salt
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2014/071005
Other languages
English (en)
Japanese (ja)
Inventor
俊夫 藤村
和田　実
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Pharmaceutical Industries Ltd
Original Assignee
Nitto Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Pharmaceutical Industries Ltd filed Critical Nitto Pharmaceutical Industries Ltd
Priority to JP2015530976A priority Critical patent/JP6554034B2/ja
Publication of WO2015020191A1 publication Critical patent/WO2015020191A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a chewable tablet which is a calcium agent and includes calcium salt and magnesium salt, a disintegrant and / or an organic acid, etc., and has excellent flavor and disintegration in the mouth.
  • Calcium is an essential mineral for living organisms, and various products such as pharmaceuticals containing calcium, health foods, and nutritional supplements are commercially available to supplement calcium (Patent Documents 1 and 2).
  • Patent Documents 1 and 2 In conventional commercial products, for example, calcium supplementation for women in pregnancy and lactation, calcium reinforcement for relieving irritations due to osteoporosis and calcium deficiency, calcium supplementation for children in the growing period, etc. have been frequently taken.
  • An object of the present invention is to provide a calcium agent (chewable tablet) that is excellent in flavor and disintegration in the mouth and is easy to take.
  • the inventors of the present invention contain a calcium salt and a magnesium salt, and further include a calcium agent containing a specific type of disintegrant, a calcium agent containing an organic acid, or a disintegration.
  • a calcium agent containing a specific type of disintegrant
  • a calcium agent containing an organic acid or a disintegration.
  • the present invention is as follows: [1] A calcium agent comprising a calcium salt and a magnesium salt, and further comprising a disintegrant. [2] A calcium agent containing a calcium salt and a magnesium salt, and further containing an organic acid. [3] A calcium agent comprising a calcium salt and a magnesium salt, and further containing a disintegrant and an organic acid.
  • Disintegrant is carboxymethyl starch sodium, carmellose, carmellose calcium, carmellose sodium, hydrous silicon dioxide, agar powder, croscarmellose sodium, crospovidone, light anhydrous silicic acid, crystalline cellulose, synthetic aluminum silicate, Alpha starch, partially pregelatinized starch, wheat starch, rice starch, corn starch, potato starch, dioctyl sodium sulfosuccinate, low substituted sodium carboxymethyl starch, low substituted hydroxypropyl cellulose, hydroxyethyl methyl cellulose, dextrin, tragacanth Powder, lactose hydrate, hydroxypropyl starch, D-mannitol, magnesium aluminate metasilicate, and purified agar for disintegration Calcium agent according to at least one member [1] or [3].
  • the organic acid is at least one selected from the group consisting of citric acid, malic acid, tartaric acid, gluconic acid, succinic acid, malonic acid, maleic acid, fumaric acid and ascorbic acid [2] or [3 ] Calcium agent as described in.
  • the calcium agent according to [2] or [3], wherein the organic acid is at least one selected from the group consisting of citric acid, malic acid, tartaric acid, gluconic acid, succinic acid, and fumaric acid.
  • Calcium salt is calcium carbonate, calcium lactate, calcium silicate, calcium chloride, calcium hydroxide, calcium phosphate, anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate dihydrate, calcium dihydrogen phosphate monohydrate, glucone Calcium according to any one of [1] to [7], which is at least one selected from the group consisting of calcium oxide, calcium glycerophosphate, calcium citrate, calcium L-aspartate, dolomite, borei powder and purified bovine bone meal Agent.
  • the calcium agent according to any one of [1] to [8], wherein the calcium salt is calcium carbonate.
  • the magnesium salt is at least one selected from the group consisting of magnesium carbonate, magnesium oxide, magnesium chloride, magnesium sulfate, magnesium hydroxide, magnesium aluminate silicate and organic acid magnesium [1] to [9 ]
  • the calcium agent in any one of. [11] The calcium agent according to any one of [1] to [10], wherein the magnesium salt is magnesium carbonate. [12] The calcium agent according to any one of [1] to [11], containing 10 to 90% by mass of a calcium salt based on the total amount of the calcium agent. [13] The calcium agent according to any one of [1] to [12], containing 1 to 20% by mass of a magnesium salt based on the total amount of the calcium agent.
  • Chewable tablets comprising the following (A) and (B): (A) granules containing calcium and magnesium salts; (B) A tableting aid containing at least one selected from the group consisting of a disintegrant and an organic acid.
  • the present invention by providing a calcium agent with better flavor and disintegration in the mouth, it becomes easy for even elderly people to take calcium agent, and to obtain improved compliance in continuous administration Can do. In addition, it becomes easy to take, and even a child can take continuous calcium supplements.
  • the present invention provides a calcium agent containing a calcium salt and a magnesium salt and a disintegrating agent, a calcium salt and a magnesium salt and an organic acid, or a calcium salt and a magnesium salt, and a disintegrating agent and an organic acid.
  • the calcium preparation of the present invention contains calcium and magnesium, and is supplemented with calcium in osteoporosis, the growth period, pregnancy / lactation period, etc., and a RANKL inhibitor that is a calcium / natural vitamin D3 / magnesium compound ( It has uses such as treatment and prevention of hypocalcemia associated with administration of denosumab (genetical recombination).
  • the calcium salt used in the present invention is calcium carbonate, calcium lactate, calcium silicate, calcium gluconate, calcium chloride, calcium hydroxide, calcium phosphate, anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate dihydrate, dihydrogen phosphate.
  • examples include, but are not limited to, calcium monohydrate, calcium glycerophosphate, calcium citrate, calcium L-aspartate, calcium alginate, water-soluble calcium salt, and the like.
  • a calcium complex containing a calcium salt such as calcium-EDTA, dolomite, borei powder, and purified beef bone meal can be used.
  • calcium carbonate, calcium lactate, calcium gluconate, calcium hydrogen phosphate dihydrate and the like are preferable. More preferably, it is calcium carbonate.
  • various polymorphs such as calcite, aragonite, vaterite, and amorphous (amorphous) can also be used. More preferably, it is precipitated calcium carbonate.
  • the content of the calcium salt in the calcium agent of the present invention is 10 to 90% by mass, preferably 20 to 85% by mass, particularly preferably 30 to 80% by mass, based on the total amount of the calcium agent.
  • magnesium salt used in the present invention examples include magnesium carbonate, magnesium oxide, magnesium chloride, magnesium sulfate, magnesium hydroxide, magnesium silicate aluminate, organic acid magnesium (magnesium lactate, magnesium gluconate, etc.), etc. It is not limited to. Preferably, magnesium carbonate, magnesium oxide, magnesium hydroxide, etc. are mentioned, More preferably, magnesium carbonate is mentioned.
  • Magnesium is mainly stored in the vicinity of the bone surface as magnesium ions. When metabolism is insufficient, calcium ions are replaced and magnesium is replenished into the body. Magnesium is involved in calcium metabolism.
  • the content of the magnesium salt in the calcium agent of the present invention is 1 to 20% by mass, preferably 2 to 15% by mass, particularly preferably 3 to 10% by mass, based on the total amount of the calcium agent.
  • Disintegrants used in the present invention include croscarmellose sodium, carmellose calcium, carmellose, carmellose sodium, celluloses such as low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, low-substituted carboxymethyl starch sodium, Carboxymethyl starch, hydroxypropyl starch, pregelatinized starch, partially pregelatinized starch, wheat starch, rice starch, corn starch, potato starch, etc., hydrous silicon dioxide, agar powder, crospovidone, light anhydrous silicic acid, crystalline cellulose Synthetic aluminum silicate, dioctyl sodium sulfosuccinate, hydroxyethyl methyl cellulose, dextrin, tragacanth powder, lactose hydrate, D- N'nitoru, magnesium aluminometasilicate, although breakdown purified agar, and the like, without limitation.
  • celluloses such as low-substituted hydroxy
  • L-HPC low-substituted hydroxypropylcellulose
  • crospovidone croscarmellose sodium and the like listed in the Japanese Pharmacopoeia. More preferred are L-HPC and crospovidone. These can use a commercial item suitably.
  • the content of the disintegrant in the calcium agent of the present invention is 0.1 to 30% by mass, preferably 0.2 to 20% by mass, particularly preferably 0.3 to 10% by mass, based on the total amount of the calcium agent.
  • Examples of the organic acid used in the present invention include, but are not limited to, monocarboxylic acids having 6 or less carbon atoms, dicarboxylic acids, trivalent or higher polyvalent carboxylic acids, hydroxycarboxylic acids, and carboxylic anhydrides.
  • Examples of hydroxycarboxylic acids include citric acid, malic acid, DL-malic acid, tartaric acid, gluconic acid, succinic acid, malonic acid, glutaric acid, maleic acid, fumaric acid, glutaconic acid, ascorbic acid, and the like. It is not limited. Moreover, the mixture of 1 or more types of these may be sufficient.
  • malic acid DL-malic acid, tartaric acid, gluconic acid, succinic acid, malonic acid, maleic acid, fumaric acid, citric acid, ascorbic acid and the like, more preferably malic acid, DL-malic acid, tartaric acid , Succinic acid, fumaric acid and citric acid, particularly preferably DL-malic acid and citric acid.
  • the content of the organic acid in the calcium agent of the present invention is 0.01 to 50% by mass, preferably 0.02 to 30% by mass, particularly preferably 0.03 to 20% by mass, based on the total amount of the calcium agent.
  • the dosage and frequency of administration of the calcium preparation of the present invention depends on the age, weight, health status, sex, degree of medical condition or combination of drugs being taken, or other factors if treatment is being performed. Can be determined. For example, about 10 to 150 mg / kg (body weight) per day, preferably about 20 to 100 mg / kg (body weight), more preferably 30 to 60 mg / kg (body weight) 1 to 4 times, more preferably Can be taken once or twice. More specifically, per day, calcium as 1-20 mg / kg (body weight), preferably 5-15 mg / kg (body weight), and magnesium as 0.05-1 mg / kg (body weight), preferably 0.25-0.75 mg. / Kg (body weight) can be taken.
  • the calcium preparation of the present invention may contain other components described later, for example, nutrients such as minerals and vitamins, drugs and additives, but is not limited thereto.
  • Examples of minerals include, but are not limited to, zinc and selenium.
  • vitamins examples include, but are not limited to, vitamin B (B1, B2, B3, B5, B6, etc.), vitamin C, vitamin D (D2, D3, D4, D5, etc.), vitamin K, and the like. Vitamin D is preferable, and vitamin D3 (cholecalciferol) is more preferable.
  • vitamins commercially available products can be used. For example, commercially available products (such as RIKEN DRY D3-B5N-GP) can be used for vitamin D3. It does not matter whether it is natural or synthetic. Natural vitamins are preferred.
  • Additives include, but are not limited to, excipients, binders, colorants, flavoring agents, lubricants, and the like.
  • preservatives, color formers, fragrances, stabilizers, acidulants and the like that are generally used in foods can also be added. Examples thereof include ethyl vanillin, vanillin, glycerin fatty acid ester, medium chain fatty acid triglyceride and the like.
  • These additives are used in amounts conventionally used in the technical field of pharmaceutical preparations. These additives may be used by mixing two or more kinds at an appropriate ratio.
  • excipients include, but are not limited to, maltitol, maltol, erythritol, D-mannitol, D-sorbitol, xylitol, purified sucrose, sucrose, fructose, glucose, powdered reduced maltose syrup, and lactose.
  • binder examples include, but are not limited to, hydroxypropyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, pullulan, macrogol, gum arabic, gum arabic powder, and gelatin.
  • the colorant examples include, but are not limited to, one or more components selected from edible pigments such as edible yellow No. 5, edible red No. 2, and edible blue No. 2, edible lake pigments, and iron sesquioxide. .
  • Any flavoring agent may be used as long as it is used as a sweetener, a refreshing agent, a fragrance or the like.
  • yogurt flavor vanilla flavor, aspartame, amateur powder, saccharin, caramel, cinnamon powder, dipotassium glycyrrhizinate, stevia, mint oil, orange oil, lemon oil, pine oil, 1-menthol, fruit flavor, chocolate flavor, etc.
  • a yogurt flavor is mentioned.
  • Lubricants include, but are not limited to, magnesium stearate, calcium stearate, talc, sodium lauryl sulfate, light anhydrous silicic acid, hydrous silicon dioxide, sucrose fatty acid ester and the like. More preferred are magnesium stearate and talc.
  • the calcium preparation of the present invention can be taken in combination with a drug.
  • the drug can be appropriately determined according to the health condition, sex, degree of medical condition, etc. of the subject.
  • examples of the drug include, but are not limited to, vitamins, RANKL inhibitors (such as denosumab), and citric acid agents.
  • Examples of the dosage form of the calcium preparation of the present invention include tablets, chewable tablets and the like, and chewable tablets are preferred.
  • the calcium agent of the present invention is excellent in disintegration in the mouth, and can be disintegrated, for example, in 0.5 to 30 minutes, preferably in several minutes (eg, 1 to 2 minutes).
  • the calcium agent chewable tablets of the invention can disintegrate within 15 minutes, preferably within 10 minutes, more preferably within 2 minutes.
  • the disintegration time can be measured according to the method for operating an immediate release preparation according to the 16th revised Japanese Pharmacopoeia disintegration test method.
  • the hardness when the calcium agent of the present invention is made into a chewable tablet is 2 to 20 kp, preferably 3 to 15 kp, more preferably 4 to 10 kp in terms of storage management.
  • the hardness is measured by a commonly used tablet hardness measuring device, for example, a tablet hardness tester manufactured by Schleuniger. Such desired hardness can be obtained by compression pressure at the time of tableting and preparation of components. If the hardness is lower than this range, damage tends to occur during the manufacturing, packaging, distribution process, and the like, and if it is higher, it tends to be difficult to chew.
  • the tablet in the present invention can be obtained using a general granulation method. That is, after sufficiently mixing the above calcium salt, excipient, and other additives as necessary, granulation is performed using a lower alcohol such as ethanol or isopropanol, or water that may contain the lower alcohol. After drying, sizing as necessary, tableting is performed with a tableting machine to form tablets. Alternatively, the mixed powder can be compressed into tablets by a direct compression method. As an example, it will be described in the following examples, but is not limited to this method.
  • Examples of the apparatus used for granulation include, but are not limited to, a vertical granulator, a high shear mixer, a high speed mixer, a planetary mixer, and the like.
  • Another embodiment of the present invention includes a chewable tablet comprising the following (A) and (B): (A) granules containing calcium and magnesium salts; (B) A tableting aid containing a disintegrant or an organic acid or a mixture thereof.
  • the “tableting aid” means a component mixed with the granules of (A) before the tableting step in the production of chewable tablets.
  • the tableting aid (B) may contain one or more of the specific disintegrant and organic acid described above.
  • the tableting aid (B) contains additives conventionally used in the pharmaceutical field. As this additive, the above-mentioned further additive etc. are mentioned, for example. These additives are used in conventional amounts in the pharmaceutical field unless otherwise specified.
  • the tableting aid (B) may contain two or more of these additives in an appropriate ratio.
  • the content of the disintegrant contained in the tableting aid (B) in the chewable tablet of the present invention is usually 0.1 to 30% by mass, preferably 0.2 to 20% by mass, more preferably 0.3 to 10% by mass.
  • the content of the organic acid contained in the tableting aid (B) in the chewable tablet of the present invention is usually 0.01 to 50% by mass, preferably 0.02 to 30% by mass, more preferably 0.03 to It is 20% by mass, particularly preferably 0.1 to 10% by mass, most preferably 0.3 to 5% by mass.
  • the weight of the chewable tablet of the present invention is not particularly limited, but is 200 to 2000 mg, preferably 300 to 1500 mg per tablet.
  • Chewable tablets containing the following (a) and (b): (A) calcium salt (preferably calcium carbonate, calcium lactate, calcium gluconate, calcium hydrogen phosphate dihydrate) and magnesium salt (preferably magnesium carbonate, magnesium oxide, magnesium hydroxide); excipient (preferably Sucrose, gelatin, sorbitol, mannitol) and binder (preferably polyvinylpyrrolidone); and optionally stabilizers (preferably glycerin fatty acid esters), emulsifiers (preferably medium chain fatty acid triglycerides, lauric acid) Granules consisting of sorbitan); (B) a disintegrant (preferably low-substituted hydroxypropylcellulose (L-HPC), crospovidone, croscarmellose sodium, or a mixture thereof), an organic acid (preferably malic acid, DL-malic acid, tartaric acid, A tableting aid comprising fumaric
  • the chewable tablet (A) can be produced according to the following production process.
  • Granule (A) can be produced by, for example, mixing calcium salt and magnesium salt together with additives and granulating this mixture. More specifically, a solvent dispersion of a binder is added and granulated. The product is then dried and the resulting granulated product is crushed to obtain a sized powder.
  • a tableting aid (B) is added to the granulated powder and mixed to obtain granules for tableting. (3) The granules are tableted with a tableting machine to obtain uncoated tablets.
  • the calcium preparation of the present invention can be applied to pharmaceuticals (medical drugs or over-the-counter drugs), foods, and the like.
  • the drug includes osteoporosis, developmental period, calcium supplementation in pregnancy, lactation, etc., and calcium / natural vitamin D3 / magnesium combination agent (RANKL inhibitor (denosumab (genetical recombination) etc.)
  • RNKL inhibitor denosumab (genetical recombination) etc.
  • it is not limited to these, but the use such as treatment and prevention of hypocalcemia associated with administration is included, but it is not limited thereto.
  • Examples of foods include, but are not limited to, health foods, nutritional supplements (supplements), foods for specified health use, and the like.
  • Reference example Precipitated calcium carbonate 6,100g, magnesium carbonate 473.6g, sucrose powder 1,885.2g was mixed using a high-speed mixer (FS-GS-25 manufactured by Earth Technica) and then using a flow coater (Freund Sangyo FlO-5A). Granulate and dry while adding 184 g of polyvinylpyrrolidone dissolved in 1,042 g of purified water, and use a power mill (P-3S made by Showa Kagaku Kikai) and a circular vibratory sieve (TM-40-2S made by Deoksugakusho). And sized to obtain a sized powder.
  • disintegrating agent When disintegrating agent is added 864.28 g of the sized powder prepared in Reference Example and 18.4 g of low-substituted hydroxypropylcellulose, 32 g of vitamin D3 (RIKEN), 4.4 g of magnesium stearate and 1.15 g of yogurt flavor as a disintegrating agent Then, it was compressed with a rotary tableting machine (HT-AP15SS-II type, manufactured by Hata Seiko Co., Ltd.) to produce 1 tablet of 1,150 mg. Tablet hardness was 7.81 kp on average, and sufficient hardness as a tablet (chewable tablet) was obtained.
  • a rotary tableting machine HT-AP15SS-II type, manufactured by Hata Seiko Co., Ltd.
  • disintegrating agent When disintegrating agent is added 864.28 g of the sized powder prepared in Reference Example and 46 g of low-substituted hydroxypropylcellulose, 32 g of vitamin D3 (RIKEN), 4.4 g of magnesium stearate, and 1.15 g of yogurt flavor as a disintegrating agent are mixed.
  • the tablet was compressed with a rotary tableting machine (HT-AP15SS-II type, manufactured by Hata Seiko Co., Ltd.) to produce 1185 mg tablet. Tablet hardness was 7.15 kp on average, and sufficient hardness as a tablet (chewable tablet) was obtained.
  • disintegrating agent When disintegrating agent is added 864.28 g of the sized powder prepared in Reference Example and 46 g of crospovidone, 32 g of vitamin D3 (RIKEN), 4.4 g of magnesium stearate and 1.15 g of yogurt flavor as a disintegrating agent are added and mixed.
  • the tablet was compressed with a tablet machine (HT-AP15SS-II, manufactured by Hata Seiko Co., Ltd.) to produce 1 tablet of 1,185 mg. Tablet hardness was 7.16 kp on average, and sufficient hardness as a tablet (chewable tablet) was obtained.
  • disintegrant and organic acid 864.28g sized powder prepared in Reference Example 18.4g crospovidone as disintegrant, 18.4g malic acid as organic acid, 32g vitamin D3 (RIKEN), 4.4g magnesium stearate, yogurt Fragrance 1.15 g was added and mixed, and compressed with a rotary tableting machine (HT-AP15SS-II type, manufactured by Hata Seiko Co., Ltd.) to produce 1,173 mg tablets. Tablet hardness was 8.83 kp on average, and sufficient hardness as a tablet (chewable tablet) was obtained.
  • a rotary tableting machine HT-AP15SS-II type, manufactured by Hata Seiko Co., Ltd.
  • disintegrant and organic acid 864.28g sized powder prepared in Reference Example 18.4g crospovidone as disintegrant, 18.4g citric acid as organic acid, 32g vitamin D3 (RIKEN), 4.4g magnesium stearate, yogurt Fragrance 1.15 g was added and mixed, and compressed with a rotary tableting machine (HT-AP15SS-II type, manufactured by Hata Seiko Co., Ltd.) to produce 1,173 mg tablets. Tablet hardness was 8.4 kp on average, and sufficient hardness as a tablet (chewable tablet) was obtained.
  • a rotary tableting machine HT-AP15SS-II type, manufactured by Hata Seiko Co., Ltd.
  • the disintegration time was significantly shortened in Examples 1 to 3 to which a disintegrant was added. Also in Examples 4 to 8 in which an organic acid was added, the disintegration time was significantly shortened compared to the reference example. In particular, in the example in which the disintegrant and the organic acid were added, the disintegration time was about 2 minutes, and the result was very short.
  • the present invention relates to a calcium agent containing calcium salt and magnesium salt as active ingredients, for disintegrating agents, organic acids, etc., for problems such as powderiness of calcium salt and improvement of dosage for the elderly with weak biting power, etc. It has been clarified that the addition of can improve the disintegration as well as the feeling of administration, resulting in a more soluble calcium preparation. By this invention, it becomes possible to improve the compliance of the subject who takes a calcium agent.
  • the calcium agent of the present invention can be applied to various fields such as pharmaceuticals and foods, and the present invention is extremely useful industrially.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent calcique qui est facilement ingéré et présente un goût amélioré, de meilleures propriétés de délitement dans la bouche, et équivalents. L'agent calcique présente un meilleur goût, de meilleures propriétés de délitement dans la bouche, et équivalents, grâce à l'ajout d'un agent de délitement et/ou d'un acide organique ou équivalent à un sel de calcium et un sel de magnésium.
PCT/JP2014/071005 2013-08-09 2014-08-08 Agent calcique Ceased WO2015020191A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015530976A JP6554034B2 (ja) 2013-08-09 2014-08-08 カルシウム剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2013166857 2013-08-09
JP2013-166857 2013-08-09
JP2013-189790 2013-09-12
JP2013189790 2013-09-12

Publications (1)

Publication Number Publication Date
WO2015020191A1 true WO2015020191A1 (fr) 2015-02-12

Family

ID=52461515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/071005 Ceased WO2015020191A1 (fr) 2013-08-09 2014-08-08 Agent calcique

Country Status (2)

Country Link
JP (1) JP6554034B2 (fr)
WO (1) WO2015020191A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109646415A (zh) * 2019-01-04 2019-04-19 达利园医药科技有限公司 一种既能有效补钙又能促进细胞发育的钙片的制备方法
CN112370429A (zh) * 2019-10-21 2021-02-19 广州富诺营养科技有限公司 一种直压型有机钙维生素d3咀嚼片及其制备方法
CN117122065A (zh) * 2022-05-19 2023-11-28 健茂生物科技股份有限公司 针对于不同血型的人服用的保健钙片
CN118873503A (zh) * 2024-08-19 2024-11-01 济南广盛源生物科技有限公司 一种宠物乳钙口服闪崩片及其制备方法与应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH114666A (ja) * 1997-06-17 1999-01-12 Otsuka Pharmaceut Co Ltd マグネシウム補給発泡剤組成物
JPH1189541A (ja) * 1997-09-19 1999-04-06 Yakult Honsha Co Ltd 塩基性ミネラル含有経口摂取用組成物
JP2001511453A (ja) * 1997-07-30 2001-08-14 メナリニ インターナショナル オペレーションズ ルクセンブルグ ソシエテ アノニマ ビタミンｄとカルシウムを含有する医薬組成物、それらの製法及び治療のための用法
JP2002529496A (ja) * 1998-11-13 2002-09-10 ナイコムド ファーマ エーエス 経口用カルシウム組成物の調製方法
JP2004534058A (ja) * 2001-06-08 2004-11-11 ビオノリカ アーゲー 調合薬、その使用方法、およびその製造方法
JP2008500290A (ja) * 2004-05-24 2008-01-10 ニコメド ファーマ エイエス カルシム含有化合物および糖アルコールを含む微粒状物
JP2008500975A (ja) * 2004-06-01 2008-01-17 ニコメド ファーマ エイエス 活性物質としてカルシウム含有化合物を含み、咀嚼し、舐め、飲み込むことのできる錠剤
JP2008517981A (ja) * 2004-10-25 2008-05-29 イタルファルマコ，ソシエダ アノニマ 経口用分散性医薬組成物
JP2008531678A (ja) * 2005-03-04 2008-08-14 ニコメド ファーマ エイエス 連続式流動床中でのカルシウム組成物の製造方法
WO2010137716A1 (fr) * 2009-05-29 2010-12-02 マイラン製薬株式会社 Comprimé à délitement oral, qui contient du carbonate de calcium précipité en tant qu'ingrédient actif

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3572620B2 (ja) * 1992-03-04 2004-10-06 大正製薬株式会社 ビタミンｄ３含有固形製剤組成物
US5330760A (en) * 1992-08-27 1994-07-19 Sterling Winthrop Inc. Effervescent antacid
FR2717387B1 (fr) * 1994-03-17 1996-10-18 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
JPH10287555A (ja) * 1997-04-14 1998-10-27 Kowa Co チュアブル錠

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH114666A (ja) * 1997-06-17 1999-01-12 Otsuka Pharmaceut Co Ltd マグネシウム補給発泡剤組成物
JP2001511453A (ja) * 1997-07-30 2001-08-14 メナリニ インターナショナル オペレーションズ ルクセンブルグ ソシエテ アノニマ ビタミンｄとカルシウムを含有する医薬組成物、それらの製法及び治療のための用法
JPH1189541A (ja) * 1997-09-19 1999-04-06 Yakult Honsha Co Ltd 塩基性ミネラル含有経口摂取用組成物
JP2002529496A (ja) * 1998-11-13 2002-09-10 ナイコムド ファーマ エーエス 経口用カルシウム組成物の調製方法
JP2004534058A (ja) * 2001-06-08 2004-11-11 ビオノリカ アーゲー 調合薬、その使用方法、およびその製造方法
JP2008500290A (ja) * 2004-05-24 2008-01-10 ニコメド ファーマ エイエス カルシム含有化合物および糖アルコールを含む微粒状物
JP2008500975A (ja) * 2004-06-01 2008-01-17 ニコメド ファーマ エイエス 活性物質としてカルシウム含有化合物を含み、咀嚼し、舐め、飲み込むことのできる錠剤
JP2008517981A (ja) * 2004-10-25 2008-05-29 イタルファルマコ，ソシエダ アノニマ 経口用分散性医薬組成物
JP2008531678A (ja) * 2005-03-04 2008-08-14 ニコメド ファーマ エイエス 連続式流動床中でのカルシウム組成物の製造方法
WO2010137716A1 (fr) * 2009-05-29 2010-12-02 マイラン製薬株式会社 Comprimé à délitement oral, qui contient du carbonate de calcium précipité en tant qu'ingrédient actif

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSUYOSHI HIBINO ET AL.: "Formulation Design of Oral-Disintegrating Tablets (Part 4", HEISEI 23 NENDO MIE PREFECTURE INDUSTRIAL RESEARCH INSTITUTE KENKYU HOKOKU, November 2012 (2012-11-01), pages 49 - 56 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109646415A (zh) * 2019-01-04 2019-04-19 达利园医药科技有限公司 一种既能有效补钙又能促进细胞发育的钙片的制备方法
CN112370429A (zh) * 2019-10-21 2021-02-19 广州富诺营养科技有限公司 一种直压型有机钙维生素d3咀嚼片及其制备方法
CN117122065A (zh) * 2022-05-19 2023-11-28 健茂生物科技股份有限公司 针对于不同血型的人服用的保健钙片
CN118873503A (zh) * 2024-08-19 2024-11-01 济南广盛源生物科技有限公司 一种宠物乳钙口服闪崩片及其制备方法与应用

Also Published As

Publication number Publication date
JP6554034B2 (ja) 2019-07-31
JPWO2015020191A1 (ja) 2017-03-02

Similar Documents

Publication Publication Date Title
JP5798642B2 (ja) 経口用医薬組成物
KR101203186B1 (ko) 약물의 맛이 차폐된 경구용 약학 조성물 및 그 제조 방법
JPWO2009151072A1 (ja) 口腔内速崩壊錠及びその製造方法
JP6554034B2 (ja) カルシウム剤
JP4689468B2 (ja) 錠剤およびその製造方法
JP2016174616A (ja) 崩壊性組成物及び易崩壊性圧縮成型物
JP5630902B2 (ja) ゾルピデム酒石酸塩含有口腔内崩壊錠の製造方法
JP4108605B2 (ja) アミノ酸含有口腔内速崩壊錠及びその製造方法
WO2004078171A1 (fr) Comprime contenant un acide amine absorbant l'eau
JP5945191B2 (ja) 口腔内速崩錠
JP2009073778A (ja) グルクロノラクトン含有固形製剤
JP5476782B2 (ja) アルギニン含有錠剤の製造方法
JP4174300B2 (ja) Ｌ−グルタミンおよびアズレンスルホン酸ナトリウムを含有する速崩錠または口腔内崩壊錠並びにその製造方法
KR20150003898A (ko) 경구 제형
JP5701371B2 (ja) スフィンゴミエリン含有サプリメント
JP6919117B2 (ja) 鉄化合物含有組成物の粒子、鉄化合物の変色抑制方法、並びに鉄化合物及びビタミンｃ含有組成物
EP1738755B1 (fr) Comprime contenant un acide amine a chaîne ramifiee et processus de fabrication de celui-ci
JP2005029557A (ja) 口腔内速崩壊性錠剤およびその製造方法
JP7360460B2 (ja) 口腔内崩壊錠及びその製造方法
JP7596190B2 (ja) コエンザイムｑ１０含有組成物、コエンザイムｑ１０含有錠剤、コエンザイムｑ１０の安定化方法、コエンザイムｑ１０安定化組成物
JP3637968B1 (ja) 胃内崩壊性錠剤
EP2491920A1 (fr) Comprime effervescent, sachet et sirop en poudre de gemifloxacine
JP5772169B2 (ja) イプリフラボン含有直打錠剤
JP2022074106A (ja) ロキソプロフェンとグリシンを含有する固形製剤及びその製造方法
JP2021187812A (ja) コエンザイムｑ１０安定化組成物、コエンザイムｑ１０を安定化するための組成物、コエンザイムｑ１０の安定化方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14834507

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015530976

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14834507

Country of ref document: EP

Kind code of ref document: A1